Literature DB >> 23424348

Emerging therapies offer new methods for treating rheumatoid arthritis.

Steve Russek1.   

Abstract

The approvals of abatacept and rituximab have invigorated the already competitive market for biologic RA treatments. The new generation of RA therapies now reaching the market presents opportunities for patients - and challenges for payers.

Entities:  

Year:  2006        PMID： 23424348      PMCID： PMC3571031     

Source DB:  PubMed          Journal:  Biotechnol Healthc        ISSN： 1554-169X


  11 in total

Review 1.  TNF inhibitors: a new age in rheumatoid arthritis treatment.

Authors:  Diana L Anderson
Journal:  Am J Nurs       Date:  2004-02       Impact factor: 2.220

Review 2.  New drugs for rheumatoid arthritis.

Authors:  Nancy J Olsen; C Michael Stein
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

3.  Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype.

Authors:  Karin Ekström Smedby; Henrik Hjalgrim; Johan Askling; Ellen T Chang; Henrik Gregersen; Anna Porwit-MacDonald; Christer Sundström; Måns Akerman; Mads Melbye; Bengt Glimelius; Hans-Olov Adami
Journal:  J Natl Cancer Inst       Date:  2006-01-04       Impact factor: 13.506

4.  The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985.

Authors:  S E Gabriel; C S Crowson; W M O'Fallon
Journal:  Arthritis Rheum       Date:  1999-03

Review 5.  The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets.

Authors:  Thomas Dörner; Gerd R Burmester
Journal:  Curr Opin Rheumatol       Date:  2003-05       Impact factor: 5.006

6.  Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.

Authors:  Mark C Genovese; Jean-Claude Becker; Michael Schiff; Michael Luggen; Yvonne Sherrer; Joel Kremer; Charles Birbara; Jane Box; Kannan Natarajan; Isaac Nuamah; Tracy Li; Richard Aranda; David T Hagerty; Maxime Dougados
Journal:  N Engl J Med       Date:  2005-09-15       Impact factor: 91.245

Review 7.  Current treatment of juvenile rheumatoid arthritis.

Authors:  Norman T Ilowite
Journal:  Pediatrics       Date:  2002-01       Impact factor: 7.124

8.  Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study.

Authors:  P Lahdenne; P Vähäsalo; V Honkanen
Journal:  Ann Rheum Dis       Date:  2003-03       Impact factor: 19.103

Review 9.  The German etanercept registry for treatment of juvenile idiopathic arthritis.

Authors:  G Horneff; H Schmeling; T Biedermann; I Foeldvari; G Ganser; H J Girschick; T Hospach; H I Huppertz; R Keitzer; R M Küster; H Michels; D Moebius; B Rogalski; A Thon
Journal:  Ann Rheum Dis       Date:  2004-04-28       Impact factor: 19.103

10.  Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience.

Authors:  D E Yocum; D E Furst; W G Bensen; F X Burch; M A Borton; L J Mengle-Gaw; B D Schwartz; W Wisememandle; Q A Mekki
Journal:  Rheumatology (Oxford)       Date:  2004-03-10       Impact factor: 7.580
View more
  1 in total

1.  Synergistic and receptor-mediated targeting of arthritic joints via intra-articular injectable smart hydrogels containing leflunomide-loaded lipid nanocarriers.

Authors:  Mariam Zewail; Noha Nafee; Maged W Helmy; Nabila Boraie
Journal:  Drug Deliv Transl Res       Date:  2021-05-19       Impact factor: 4.617
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.